{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:22:04Z","timestamp":1794396124244,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.vaccine.2021.05.067","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T08:30:12Z","timestamp":1623141012000},"page":"3892-3899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac\u00ae, compared with Engerix-B\u00ae in healthy Asian adults: A phase 3 randomized clinical trial"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-4859","authenticated-orcid":false,"given":"Francisco","family":"Diaz-Mitoma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna N.","family":"Spaans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.067_b0005","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.05.067_b0010","doi-asserted-by":"crossref","unstructured":"MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harbor perspectives in medicine. 2015;5:a021410-a. doi: 10.1101\/cshperspect.a021410","DOI":"10.1101\/cshperspect.a021410"},{"key":"10.1016\/j.vaccine.2021.05.067_b0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.28109","article-title":"Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012","volume":"63","author":"Roberts","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.vaccine.2021.05.067_b0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.05.067_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2893.2011.01499.x","article-title":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*","volume":"18","author":"Hatzakis","year":"2011","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.vaccine.2021.05.067_b0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1017\/S0950268813000940","article-title":"Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association","volume":"142","author":"Hope","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2021.05.067_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027717","article-title":"The increasing burden of imported chronic hepatitis B \u2014 United States, 1974\u20132008","volume":"6","author":"Mitchell","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.05.067_b0040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.21784","article-title":"Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California","volume":"46","author":"Lin","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2021.05.067_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.732","article-title":"Epidemiology of hepatitis B virus infection in the United States","volume":"12","author":"Hyun Kim","year":"2018","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"10.1016\/j.vaccine.2021.05.067_b0050","unstructured":"National Viral Hepatitis Action Plan 2017-2020. Office of Infectious Disease and HIV\/AIDS Policy; 2019. https:\/\/www.hhs.gov\/sites\/default\/files\/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf"},{"key":"10.1016\/j.vaccine.2021.05.067_b0055","unstructured":"World Health Organization. Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization; 2017."},{"key":"10.1016\/j.vaccine.2021.05.067_b0060","unstructured":"World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization; 2020."},{"key":"10.1016\/j.vaccine.2021.05.067_b0065","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2004.12.009","article-title":"Epidemiology of hepatocellular carcinoma","volume":"9","author":"Bosch","year":"2005","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.vaccine.2021.05.067_b0070","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4254\/wjh.v7.i12.1708","article-title":"Hepatocellular carcinoma in Asia: prevention strategy and planning","volume":"7","author":"Ashtari","year":"2015","journal-title":"World journal of hepatology."},{"key":"10.1016\/j.vaccine.2021.05.067_b0075","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Health."},{"key":"10.1016\/j.vaccine.2021.05.067_b0080","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.27969","article-title":"World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma","volume":"62","author":"de Martel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2021.05.067_b0085","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology."},{"key":"10.1016\/j.vaccine.2021.05.067_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029616","article-title":"Insight into hepatitis B prevalence and risk factors among Vietnamese Americans: a cross-sectional analysis of data from a community-based screening program","volume":"9","author":"Lee","year":"2019","journal-title":"BMJ Open."},{"key":"10.1016\/j.vaccine.2021.05.067_b0095","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.3748\/wjg.v21.i42.11924","article-title":"Hepatitis B among Asian Americans: prevalence, progress, and prospects for control","volume":"21","author":"Chen","year":"2015","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.vaccine.2021.05.067_b0100","unstructured":"Langley JM, Vesikari T, Segall N, Ward BJ, Cooper C, Poliquin G, et al. A 3-antigen hepatitis B vaccine provides consistently higher seroprotection rates (SPR) and anti-HBs titers compared to single-antigen vaccine in adults with comorbidities known to be associated with poor response to vaccinations: Results from the phase III double-blind, randomized study (PROTECT). Abstract presented at American Association for the Study of Liver Diseases (November 13 - 16,2020). Poster#0742"},{"key":"10.1016\/j.vaccine.2021.05.067_b0105","unstructured":"GlaxoSmithKline Biologicals. Engerix B [package insert]. Research Triangle Park, NC; : 2020. https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Engerix-B\/pdf\/ENGERIX-B.PDF"},{"key":"10.1016\/j.vaccine.2021.05.067_b0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0264-410X(92)90391-V","article-title":"Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein: a preliminary study on immunogenicity","volume":"10","author":"Yap","year":"1992","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.05.067_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000025276","article-title":"Stability of fresh frozen plasma: results of 36-month storage at \u201320 \u00b0C, \u201325 \u00b0C, \u201330 \u00b0C and \u201340 \u00b0C: multicenter study of the section \u2018Blood Plasma Constituents\u2019 of the Deutsche Gesellschaft f\u00fcr Transfusionsmedizin und Immunh\u00e4matologie (DGTI)","volume":"27","author":"Kotitschke","year":"2000","journal-title":"Transfus Med Hemother."},{"key":"10.1016\/j.vaccine.2021.05.067_b0120","doi-asserted-by":"crossref","unstructured":"Finn A and the CONSTANT Study Group. High HBsAb Titers Consistent Across 3 Lots of the Tri-antigenic Hepatitis B (HBV) Vaccine, Sci-B-Vac\u00ae: Results from the Second Pivotal Phase 3 Double-Blind, Randomized Controlled Trial Designed to Assess the Lot-to-Lot Consistency of Sci-B-Vac\u00ae in Adults. Abstract presented at the Digital European Association for the Study of the Liver (EASL) (27\u201329 August 2020) Oral #AS169","DOI":"10.1016\/S0168-8278(20)30675-9"},{"key":"10.1016\/j.vaccine.2021.05.067_b0125","article-title":"Efficacy and safety of a 3-antigen (pre-S1\/pre-S2\/S) hepatitis B vaccine: results of a phase 3 randomized clinical trial in the Russian Federation","author":"Esaulenko","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.05.067_b0130","article-title":"A double-blind randomized phase 2 controlled trial of intradermal hepatitis B vaccination with a topical Toll-like receptor 7 agonist imiquimod, in patients on dialysis","author":"Hung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.05.067_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.1995.tb01047.x","article-title":"Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines","volume":"10","author":"Yap","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2021.05.067_b0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jiph.2013.05.004","article-title":"Hepatitis B: report of prevalence and access to healthcare among Chinese residents in Sheffield UK","volume":"6","author":"Vedio","year":"2013","journal-title":"J Infect Public Health."},{"key":"10.1016\/j.vaccine.2021.05.067_b0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.5009\/gnl.2013.7.4.450","article-title":"Hepatitis B screening and vaccination practices in Asian American primary care","volume":"7","author":"Chu","year":"2013","journal-title":"Gut Liver."},{"key":"10.1016\/j.vaccine.2021.05.067_b0150","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1586\/erv.11.151","article-title":"Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity","volume":"10","author":"Casidy","year":"2011","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2021.05.067_b0155","first-page":"900","article-title":"Reducing liver cancer disparities: a community-based hepatitis-B prevention program for Asian-American communities","volume":"99","author":"Hsu","year":"2007","journal-title":"J Natl Med Assoc."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:57:03Z","timestamp":1759402623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21006629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0264410X21006629"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac\u00ae, compared with Engerix-B\u00ae in healthy Asian adults: A phase 3 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}